Re-evaluation Decision RVD2021-06, (S)-kinoprene and Its Associated End-use Products

Summary

To obtain a full copy of Re-evaluation Decision RVD2021-06, (S)-kinoprene and Its Associated End-use Products please contact our publications office.

Should you require further information please contact the Pest Management Information Service.

Table of contents

Re-evaluation decision for (S)-kinoprene and its associated end-use products

Under the authority of the Pest Control Products Act, all registered pesticides must be re-evaluated by Health Canada's Pest Management Regulatory Agency (PMRA) to ensure that they continue to meet current health and environmental standards and continue to have value. The re-evaluation considers data and information from pesticide manufacturers, published scientific reports and other regulatory agencies, as well as comments received during public consultations. Health Canada applies internationally accepted risk assessment methods as well as current risk management approaches and policies.

(S)-kinoprene is an insect juvenile hormone analogue that inhibits insect growth during the moulting process. It is used to control aphids and whiteflies, and suppress mealybugs on greenhouse ornamental plants. It is applied as a foliar spray. Currently registered products containing (S)-kinoprene can be found in the Pesticide Label Search and in Appendix I.

The Proposed Re-evaluation Decision PRVD2020-11, (S)-kinoprene and its Associated End-use ProductsFootnote 1 containing the evaluation of (S)-kinoprene and proposed decision, underwent a 90 day consultation period ending on 4 November 2020. In PRVD2020-11, (S)-kinoprene was found to present potential risks to certain terrestrial and aquatic organisms, however risks were shown to be acceptable with additional standard precautionary label statements to protect aquatic organisms and beneficial arthropods and with updated use directions. With respect to human health, risks were identified for occupational workers; risks were not shown to be acceptable when used according to current label directions, or when additional mitigation measure were considered. Therefore, cancellation of the registration of (S)-kinoprene and all associated end-use products for sale and use in Canada was proposed.

Health Canada received comments relating to the health and value assessments. Commenters are listed in Appendix II of RVD2021-06. These comments are summarized in Appendix III of RVD2021-06 along with the responses by Health Canada. These comments did not result in revisions to the toxicology/occupational/ or value assessments (see Science evaluation update of RVD2021-06), and did not result in changes to the proposed re-evaluation decision as described in PRVD2020-11.

A reference list of information used as the basis for the proposed re-evaluation decision is included in PRVD2020-11, and no further information was used in the final re-evaluation decision. Therefore, the complete reference list of all information used is set out in PRVD2020-11.

This document (RVD2021-06, (S)-kinoprene and Its Associated End-use Products) presents the final re-evaluation decisionFootnote 2 for the re-evaluation of (S)-kinoprene. All products containing (S)-kinoprene that are registered in Canada are subject to this re-evaluation decision.

Re-evaluation decision for (S)-kinoprene

Health Canada has completed the re-evaluation of (S)-kinoprene. Under the authority of the Pest Control Products Act, Health Canada is cancelling the registration of (S)-kinoprene and all associated end-use products. An evaluation of available scientific information found that risks to human health were not shown to be acceptable when (S)-kinoprene is used according to the current conditions of registration, or when additional mitigation is considered.

Next steps

To comply with this decision, all (S)-kinoprene products are to be phased-out following the implementation timeline outlined below. Appendix I lists the products containing (S)-kinoprene that are registered under the authority of the Pest Control Products Act.

Other information

Any person may file a notice of objectionFootnote 3 regarding this decision on (S)-kinoprene and its associated end-use products within 60 days from the date of publication of this re-evaluation decision. For more information regarding the basis for objecting (which must be based on scientific grounds), please refer to the Pesticides section of the Canada.ca website (Request a Reconsideration of Decision) or contact the PMRA's Pest Management Information Service.

The relevant confidential test data on which the decision is based on, is referenced in PRVD2020-11 and are available for public inspection, upon application, in the PMRA's Reading Room (located in Ottawa). For more information, please contact the PMRA's Pest Management Information Service by phone (1-800-267-6315) or by e-mail (hc.pmra-info-arla.sc@canada.ca).

Appendix I Registered products containing (S)-kinoprene in Canada

Table 1 Registered products containing (S)-kinoprene in Canada cancelled as a result of re-evaluationTable 1 Footnote 1
Registration Number Marketing Class Registrant Product Name Formulation Type Active ingredient
(%, g/L)
25575 Technical Wellmark International (S)-kinoprene Technical Solution 95.8%
29661 Commercial Enstar®EW Emulsifiable Concentrate 18.42%
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: